Pharos Vaccine

Pharos Vaccine is a pioneering South Korean biotechnology company dedicated to the development of advanced immunotherapies and vaccines for both human and animal health. The company leverages its proprietary technology platforms in chimeric recombinant proteins, CAR-T cell therapy, and dendritic cell (DC) technology to target intractable cancers, cardiovascular diseases, and livestock infections. Pharos Vaccine's clinical-stage human pipeline includes a CD19 CAR-T therapy for B-cell malignancies and a tolerogenic DC therapy (AMI-DC) for heart failure following myocardial infarction. In the veterinary sector, the company has commercialized its PharoVax-FMD vaccine, representing a novel recombinant protein-based approach to foot-and-mouth disease. Headquartered in Seongnam-si, Pharos Vaccine operates its own GMP manufacturing facility to support its diverse portfolio of cell and gene therapies.